Donanemab is a monoclonal antibody that the U.S. Food and Drug Administration (FDA) approved on Tuesday with the goal of slowing the progression of early-stage symptomatic Alzheimer’s disease.
Categories: $32$695 per vial000 for a year12522 for a six-month courseAlzheimer's diseaseamyloid plaquebrooke malloryBusinessDonanemabearly-stage symptomatic Alzheimer's diseaseEli LillyFDAINDIANAPOLISKisunlamonoclonal antibodyOAN NewsroomTechTECHNOLOGYTodays HeadlinesU.S. Food and Drug Administration